logo
Plus   Neg
Share
Email

Western Union Issues Outlook; Raises Quarterly Dividend - Quick Facts

The Western Union Company (WU) affirmed its three-year financial targets including operating margin of approximately 23% in 2022 and a low double-digit EPS CAGR for the three years ending 2022.

The company's 2020 outlook calls for margin expansion and adjusted EPS growth in the teens. Adjusted EPS is anticipated in a range of $1.95 to $2.05, while adjusted operating margin is projected to be approximately 21%, for the fiscal year. In adjusted constant currency, revenue is expected to grow in low single-digit, excluding any benefit related to Argentina inflation. Analysts polled by Thomson Reuters expect the company to report profit per share of $1.97. Analysts' estimates typically exclude special items.

Fourth-quarter adjusted earnings per share was $0.38 compared to $0.51, prior year. Adjusted operating margin was 18.7% compared to 19.9%. The company said the decrease in adjusted operating margin was primarily due to the higher marketing investment and the Speedpay divestiture.

Fourth-quarter revenue was $1.3 billion, a decline of 7% on a reported basis or an increase of 3% in adjusted constant currency terms.

The Western Union Company increased its quarterly dividend by 13% to $0.225 per common share, payable March 31, 2020 to shareholders of record at the close of business on March 17, 2020.

Shares of The Western Union Company were down 3% after hours.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Novacyt S.A. said it is seeing unprecedented demand for the novel coronavirus or COVID-19 diagnostic test kit developed by Primerdesign, the company's molecular diagnostics division based in the UK. As of March 27, Primerdesign has sold and received orders for more than 17.8 million pounds of its CE-Mark COVID-19 tests. Novacyt is currently selling its COVID-19 test to more than 80 countries. The U.S. Food and Drug Administration has issued an Emergency Use Authorization to allow anti-malaria drugs hydroxychloroquine sulfate and chloroquine phosphate donated to the Strategic National Stockpile as possible treatments for coronavirus (COVID-19) patients. This is the first EUA for a drug related to the COVID-19 response. Gilead Sciences Inc. said it is transitioning to "expanded access programs" from "compassionate use" programs for its experimental anti-coronavirus drug, remdesivir. The company noted that the expanded access will allow hospitals or physicians to apply for emergency use of remdesivir for multiple severely ill patients at one time, as they struggle to deal with the COVID-19 or coronavirus pandemic.
Follow RTT
>